X4 Pharmaceuticals, Inc (XFOR) Stock Forecast Nov. 3, 2026
Analysis updated on Nov. 3, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
X4 Pharmaceuticals, Inc (XFOR) stock forecast summary
Our AI scores X4 Pharmaceuticals, Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
X4 Pharmaceuticals, Inc is a small-cap company with a market capitalization of $332M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For XFOR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -28.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -16.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, XFOR included.
XFOR price chart and AI forecast
How XFOR ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
X4 Pharmaceuticals, Inc (XFOR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | XFOR | Rank |
|---|---|---|
| Market Cap | $332M | 60/60 |
| P/E Ratio | 2.28x | 15/16 |
| P/B Ratio | 2.14x | 43/50 |
| EPS | $1.47 | – |
| Book Value/Share | $1.57 | – |
| Revenue/Share | $0.09 | – |
Profitability & Margins
| Metric | XFOR | Rank |
|---|---|---|
| ROIC | -37.6% | 33/53 |
| Gross Margin | 66.5% | 15/24 |
| Operating Margin | -1003.9% | 32/40 |
| EBT Margin | -1026.2% | 34/42 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | XFOR | Rank |
|---|---|---|
| Current Ratio | 11.30x | 15/59 |
| Quick Ratio | 11.28x | 2/29 |
| D/E Ratio | 0.63x | 20/53 |
| Financial Leverage | 1.63x | 20/52 |
| Interest Coverage | -2.9x | 14/37 |
| Working Capital | $199M | 49/58 |
Cash Flow
| Metric | XFOR | Rank |
|---|---|---|
| Operating Cash Flow | -$84M | 26/56 |
Operational Efficiency
| Metric | XFOR | Rank |
|---|---|---|
| Asset Turnover | 0.03x | 31/37 |
| Receivables Turnover | 4.3x | 14/23 |
| Inventory Turnover | 5.5x | 6/23 |
| Fixed Assets Turnover | 78.9x | 2/38 |
| Days Sales Outstanding | 85 days | 10/23 |
| Days Inventory | 66 days | 18/23 |
| Payables Period | 616 days | 5/26 |
| Cash Conversion Cycle | -465 days | 17/18 |
Income Statement
| Metric | XFOR | Rank |
|---|---|---|
| Total Revenue | $9M | 33/38 |
| Operating Income | -$88M | 21/53 |
| R&D Expense | $66M | 48/55 |
| Cost of Goods Sold | $2M | 24/27 |
Dividend & Shareholder Information
| Metric | XFOR | Rank |
|---|---|---|
| Shares Outstanding | 99M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $219M | 86.5% of assets |
| Cash & Short-term Investments | $195M | 77.1% of assets |
| Accounts Receivable | $2M | 0.8% of assets |
| Inventory | $420K | 0.2% of assets |
| Total Liabilities | $98M | 38.6% of assets |
| Short-term Debt | $15M | 6.1% of assets |
XFOR quarterly financials and insider trading
X4 Pharmaceuticals, Inc (XFOR) industry peers
Companies classified under the same SEC industry code as X4 Pharmaceuticals, Inc (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| XFOR X4 Pharmaceuticals, Inc | $332M | |
| AMGN Amgen Inc | $251.64B | |
| GILD Gilead Sciences, Inc. | $211.20B | |
| MRNA Moderna, Inc. | $88.16B | |
| ARGX Argenx Se | $54.15B | |
| RVMD Revolution Medicines, Inc. | $40.33B | |
| BIIB Biogen Inc. | $36.53B | |
| BNTX Biontech Se | $22.30B | |
| EXEL Exelixis, Inc. | $17.38B | |
| NBIX Neurocrine Biosciences Inc | $14.88B | |
| HALO Halozyme Therapeutics, Inc. | $14.86B | |
| TECH Bio-Techne Corp | $11.40B | |
| RGEN Repligen Corp | $11.06B | |
| QGEN Qiagen N.V. | $10.92B | |
| KYMR Kymera Therapeutics, Inc. | $10.60B | |
| PCVX Vaxcyte, Inc. | $9.02B | |
| KRYS Krystal Biotech, Inc. | $8.76B | |
| IBRX Immunitybio, Inc. | $8.43B | |
| TWST Twist Bioscience Corp | $8.09B | |
| KOD Kodiak Sciences Inc. | $6.23B | |
| IMVT Immunovant, Inc. | $5.87B | |
| CGON Cg Oncology, Inc. | $5.49B | |
| SRRK Scholar Rock Holding Corp | $5.23B | |
| CRSP Crispr Therapeutics Ag | $4.83B | |
| ADPT Adaptive Biotechnologies Corp | $4.50B | |
| RLAY Relay Therapeutics, Inc. | $4.02B | |
| IOVA Iovance Biotherapeutics, Inc. | $3.63B | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.26B | |
| DNLI Denali Therapeutics Inc. | $3.03B | |
| LIFE Atyr Pharma Inc | $2.72B | |
| BEAM Beam Therapeutics Inc. | $2.67B | |
| ADMA Adma Biologics, Inc. | $2.48B | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.29B | |
| VCEL Vericel Corp | $2.20B | |
| BCRX Biocryst Pharmaceuticals Inc | $2.16B | |
| VIR Vir Biotechnology, Inc. | $1.99B | |
| COAG Hemab Therapeutics Holdings, Inc. | $1.92B | |
| MESO Mesoblast Ltd | $1.86B | |
| MAZE Maze Therapeutics, Inc. | $1.69B | |
| NVAX Novavax Inc | $1.66B | |
| ALVO Alvotech | $1.66B | |
| REPL Replimune Group, Inc. | $1.66B | |
| IMCR Immunocore Holdings Plc | $1.53B | |
| TSHA Taysha Gene Therapies, Inc. | $1.30B | |
| VOR Vor Biopharma Inc. | $1.14B | |
| IMTX Immatics N.V. | $965M | |
| CGEM Cullinan Therapeutics, Inc. | $961M | |
| ODTX Odyssey Therapeutics, Inc. | $939M | |
| MGTX Meiragtx Holdings Plc | $932M | |
| GLUE Monte Rosa Therapeutics, Inc. | $907M | |
| PRME Prime Medicine, Inc. | $805M | |
| SLBT Sl Science Holding Ltd | $724M | |
| SANA Sana Biotechnology, Inc. | $718M | |
| SLDB Solid Biosciences Inc. | $665M | |
| DNA Ginkgo Bioworks Holdings, Inc. | $663M | |
| FDMT 4d Molecular Therapeutics, Inc. | $628M | |
| AURA Aura Biosciences, Inc. | $625M | |
| CADL Candel Therapeutics, Inc. | $621M | |
| DBVT Dbv Technologies S.A. | $536M | |
| ENTX Entera Bio Ltd. | $535M |
Where XFOR sits on the market map
X4 Pharmaceuticals, Inc (XFOR) stock news
Loading...
X4 Pharmaceuticals, Inc (XFOR) stock forecast FAQ
What is the X4 Pharmaceuticals, Inc (XFOR) stock forecast?
Our AI scores X4 Pharmaceuticals, Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are X4 Pharmaceuticals, Inc stock predictions?
For XFOR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -28.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -16.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are X4 Pharmaceuticals, Inc forecasts updated?
X4 Pharmaceuticals, Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 3, 2026.
Which companies are X4 Pharmaceuticals, Inc's industry peers?
60 issuers in our coverage, XFOR included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.